Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
525.1 USD | +0.30% | +1.38% | -0.34% |
02:28pm | Utah Continued to Face Issues After UnitedHealth Claimed Progress With Hack Repairs | MT |
May. 20 | UnitedHealth's unit to launch new drug pricing model next year | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company benefits from high valuations in earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-0.34% | 482B | B- | ||
+16.35% | 127B | A- | ||
+11.89% | 95.56B | B- | ||
-22.38% | 42.85B | A- | ||
+6.05% | 41.84B | B- | ||
-4.87% | 20.06B | B- | ||
-27.30% | 2.61B | C+ | ||
-11.79% | 1.42B | B- | ||
+1.60% | 460M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- UNH Stock
- Ratings UnitedHealth Group Inc.